Cancer

Title Average Ratingsort ascending
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Glioblastoma Multiforme 50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Carbon-ion treatment 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. 50.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non 50.00%
Results of Ukrain monotherapy of prostate cancer 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom 50.00%
Role of everolimus in the treatment of renal cell carcinoma. 50.00%
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. 50.00%
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit 50.00%
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 50.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer 50.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? 50.00%
Some pharmacological properties of prolonged administration of Ukrain in rodents 50.00%
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 50.00%
An RF hyperthermia electrode which generates no edge effect. 50.00%
Cancer Prevention 50.00%
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp 50.00%
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother 50.00%
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. 50.00%
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line 50.00%
Tumoral angiogenesis: review of the literature. 50.00%
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... 50.00%
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study 50.00%
Melatonin 45.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Pancreatic cancer stem cells - insights and perspectives. 40.00%
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats 40.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. 40.00%
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. 40.00%
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. 40.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. 40.00%
Mistletoe in conventional oncological practice: exemplary cases. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. 40.00%
Long term outcomes following surgical resection of myxopapillary ependymomas. 40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. 40.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Enhancement of macrophage tumouricidal activity by the alkaloid derivative 40.00%
Trans Arterial Chemo Embolization(TACE) 40.00%
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. 40.00%
Ependymoma. 40.00%
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) 40.00%
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. 40.00%
Bioavailability of sorafenib tablets administered as a liquid suspension. 30.00%
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe 30.00%
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy 30.00%
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. 30.00%
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. 30.00%
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. 30.00%
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of m 30.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... 30.00%
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the 30.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
Dendritic Cell Therapy 30.00%
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... 30.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. 20.00%
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs 20.00%
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm 20.00%
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) 20.00%
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. 20.00%
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. 10.00%
High Dose Intravenous Vitamin C 10.00%
Herbal Based Cancer Therapies 10.00%
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........
Aging: gene silencing or gene activation?
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retar
Teratological evaluation of Ukrain in hamsters and rats
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.
Evaluation of mutagenic, genotoxic and transforming properties of Ukrain
Spike Protein Goes to Nucleus and Impairs DNA Repair (In-Vitro Study)
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort s
Breast Cancer
Homeopatic therapy in Cancer Treatment
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative....
Breast Cancer Treatment

Pages